Galderma launches phase 3 atopic dermatitis trial for nemolizumab

TAGS

Galderma, a Nestle-owned Swiss pharma company, said that it has enrolled the first patients in a phase 3 clinical study evaluating nemolizumab for the of moderate-to-severe atopic dermatitis.

The late-stage will feature adult patients, who are randomly grouped in a double-blinded, placebo-controlled study that will assess the efficacy and safety of the investigational drug for the skin disease.

Nemolizumab is a monoclonal antibody that inhibits signaling of IL-31, which is a cytokine known for playing a significant role in the pathogenesis of moderate-to-severe atopic dermatitis.

See also  Roche acquires DNA sequencing technology company Stratos Genomics

Originally developed by Chugai Pharmaceutical, nemolizumab was licensed subsequently in 2016 to .

Galderma enrolls first patients in phase 3 atopic dermatitis trial for nemolizumab

Galderma enrolls first patients in phase 3 atopic dermatitis trial for nemolizumab. Image courtesy of arztsamui at FreeDigitalPhotos.net.

Atopic dermatitis is considered to be a serious, chronic form of associated with a high burden of disease linked to itch, poor quality of sleep, and substantial quality of life impairment.

Thibaud Portal – Galderma Global Vice President, Prescription medicines, said:  “We are advancing the development of nemolizumab as planned. The Phase 2 results showed clear clinical benefits, adding to the growing scientific evidence that the IL-31 pathway may be an important driver in atopic dermatitis.

See also  Innovent Biologics, Sanofi to expedite development of cancer drugs in China

“We are committed to continuing our work to bring new therapies to patients with moderate-to-severe atopic dermatitis.”

At the 2019 American Academy of Dermatology Annual Meeting, Galderma released the final results from a phase 2b clinical trial of nemolizumab in patients with moderate-to-severe atopic dermatitis, which has been published in the Journal of Allergy and Clinical Immunology recently.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This